Unicycive Therapeutics, Inc (UNCY): Net earnings per share (EPS TTM)

UNCY (Unicycive Therapeutics) - company brandmark

The absence of commercial sales due to the R&D stage eliminates current profits for Unicycive Therapeutics (UNCY). This 12-month EPS chart on GURU.Markets contains data where this metric equals -1.51. Effective budget management supports the development of kidney therapy, while the patent purity of the innovative oral drug creates potential for expansion into a high-margin market.

UNCY Unicycive Therapeutics, Inc Earnings per share for the last 12 months (07/04/2022 - 11/17/2026)

Analytical breakdowns and data insights for company Unicycive Therapeutics (UNCY)

Analysis of all company metrics:UNCY - Unicycive
Flagship merchandise of Unicycive Therapeutics, Inc

This metric aggregates net income over a rolling year, excluding quarterly anomalies and accounting distortions. It measures the actual efficiency of profit generation per ordinary share. For Unicycive Therapeutics (UNCY), this indicator reflects the monetization of patents for innovative drugs treating hyperphosphatemia. The capitalization of its technological advantage over conventional medications directly impacts the financial result. The trend of current earnings per share over the last 12 months confirms the transparency of the business model.